---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-038030"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:39:52.229338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avalo eliminates $35M debt, Q3 net loss $5.2M; cash $10.2M; divests 800 series for up to $45M

## Summary
- Paid off remaining $14.3M of $35M debt to Horizon Technology; all loan obligations satisfied.
- Divested AVTX-800 series to AUG for up to $45M in milestone payments; pipeline focused on immunology.
- Q3 2023 net loss $5.2M ($0.11 diluted loss) vs net income $3.2M a year ago; revenue fell to $236K from $14.9M.
- Cash and cash equivalents $10.2M at Sept 30, 2023; raised $46.2M net from equity financings in 9 months.
- Advancing quisovalimab (anti-LIGHT mAb) toward planned ulcerative colitis trial; AVTX-008 BTLA agonist progressing to IND.

## SEC filing metadata
- accession: 0001628280-23-038030
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/0001628280-23-038030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/avtx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-038030
- JSON: https://secwatch.observer/filing/0001628280-23-038030.json
- Plain text: https://secwatch.observer/filing/0001628280-23-038030.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Avalo Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/0001628280-23-038030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.